SCHEMBL20576

SCHEMBL20576

Nc1nc2[nH]cnc2c(=O)n1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNP P00491 3/20 0.34
PARP1 P09874 2/20 0.33
DPP4 P27487 1/20 0.32
ABL1 P00519 2/20 0.31
RIN1 Q13671 1/20 0.31
ATAD2 Q6PL18 1/20 0.31
GDA Q9Y2T3 1/20 0.31
IP6K1 Q92551 1/20 0.31
LMNA P02545 1/20 0.30
CYP1A2 P05177 1/20 0.30
MAPT P10636 1/20 0.30
ADORA2A P29274 2/20 0.30
ADORA2B P29275 2/20 0.30
AURKA O14965 1/20 0.30
DAPK3 O43293 1/20 0.30
JAK2 O60674 1/20 0.30
PRKD3 O94806 1/20 0.30
MAP4K4 O95819 1/20 0.30
PAK4 O96013 1/20 0.30
CSF1R P07333 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL1404464 0.83 KDM4E (0.37) LMNAPDE4APDE4BPDE4CPDE4D
SCHEMBL3259641 0.81 PNP (0.35) PNPPARP1ABL1RIN1ATAD2
SCHEMBL8886026 0.81 PNP (0.35) PNPPARP1ABL1RIN1ATAD2
SCHEMBL2983845 0.79 PNP (0.34) PNPPARP1ABL1RIN1ATAD2
SCHEMBL6168437 0.79 PNP (0.34) PNPPARP1ABL1RIN1ATAD2
SCHEMBL1843775 0.79 PNP (0.34) PNPPARP1ABL1RIN1ATAD2
SCHEMBL20866 0.79 ATAD2 (0.41) PNPATAD2LMNACYP1A2MAPT
SCHEMBL2051359 0.79 PNP (0.34) PNPPARP1ABL1RIN1ATAD2
SCHEMBL1828928 0.79 PNP (0.34) PNPPARP1ABL1RIN1ATAD2
SCHEMBL6821768 0.79 GDA (0.39) PNPPARP1GDAPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630867-B2 Devices for CRISPR effector system based diagnostics THE BROAD INSTITUTE, INC. (US) 2026-05-19 US disclosed
US-20250243471-A1 PROGRAMMABLE PATTERN RECOGNITION COMPOSITIONS BROAD INST INC (US) 2025-07-31 US disclosed
US-20250223580-A1 PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS THE BROAD INSTITUTE, INC. 2025-07-10 US disclosed
US-20250129355-A1 PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS NATIONAL INSTITUTES OF HEALTH 2025-04-24 US disclosed
US-20250075268-A1 CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-03-06 US disclosed
US-12203145-B2 CRISPR effector system based diagnostics for virus detection THE BROAD INSTITUTE, INC. (US) 2025-01-21 US disclosed
EP-4119663-B1 CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS BROAD INST INC (US) 2024-11-27 EP disclosed
CN-111448311-B Diagnostic system based on multiple effector CRISPR 博德研究所 2024-11-19 CN disclosed
CN-111108220-B Diagnostic based on CRISPR effect system for virus detection 博德研究所 2024-11-19 CN disclosed
US-20240352454-A1 MULTI-EFFECTOR CRISPR BASED DIAGNOSTIC SYSTEMS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2024-10-24 US disclosed
EP-1546164-A1 (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF LG Life Sciences Ltd. (KR) 2005-06-29 EP disclosed
US-20040127454-A1 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases RESPROTECT GMBH (DE) 2004-07-01 US disclosed
WO-2004029064-A1 (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF LG LIFE SCIENCES LTD. (KR) 2004-04-08 WO disclosed
EP-1334109-A2 IMPROVED SYNTHESIS OF PURINE LOCKED NUCLEIC ACID ANALOGUES Santaris Pharma A/S (DK) 2003-08-13 EP disclosed
US-20020086998-A1 Synthesis of purine locked nucleic acid analogues SANTARIS PHARMA A/S (DK) 2002-07-04 US disclosed
WO-2002028875-A2 IMPROVED SYNTHESIS OF PURINE LOCKED NUCLEIC ACID ANALOGUES CUREON A/S (DK) 2002-04-11 WO disclosed
WO-2002024323-A2 HIGH DENSITY MOLECULAR ARRAYS ON POROUS SURFACES PICOLITER INC. (US) 2002-03-28 WO disclosed
EP-0824536-B1 ANTIMALARIAL ORGANOMETALLIC IRON COMPLEXES UNIV LILLE SCIENCES TECH (FR) 2001-08-22 EP disclosed
EP-0338168-A1 Phosphonoalkylpurine derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1989-10-25 EP disclosed
US-4508898-A Antiviral triazine compounds SYNTEX (U.S.A.) INC. 1985-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086998-A1 Synthesis of purine locked nucleic acid analogues RNGTT, PNP, UNG PNP 2/4885PARP1 147/4885DPP4 312/4885
US-20040127454-A1 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases PNP, TYMP, ENTPD5 PNP 1/4885PARP1 985/4885DPP4 469/4885
US-12630867-B2 Devices for CRISPR effector system based diagnostics ZFR, MTREX, ADAR PNP 2592/4885PARP1 981/4885DPP4 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.